The company
Xencor, Inc.
XNCR · Nasdaq
XNCR stood above a rising 150-day average in 27 of the last 52 weekly readings, including each of the last 13 weeks. It is 31.5% above that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).
Statistics
- Rotation
- Leading
- Weeks in an uptrend
- 13 in a row
- Industry in uptrend
- 16% -15 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $4.9M
- Officials’ trades on record
- 1
- Institutions holding
- 190 (+4)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 27 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
1 disclosed lines: House 0, Senate 0, executive 1; 1 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 29 Jul 2026filed 22 Sep 2026 |
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Ellen FeigalDirector | sold | 6,843at $13.06 | 18 Jun 2026filed 22 Jun 2026 |
| Kevin Charles GormanDirector | sold | 7,527at $12.31 | 15 Jun 2026filed 17 Jun 2026 |
| Richard J. RanieriDirector | sold | 5,474at $12.31 | 15 Jun 2026filed 17 Jun 2026 |
| Alan Bruce MontgomeryDirector | sold | 5,064at $12.31 | 15 Jun 2026filed 17 Jun 2026 |
| Kurt A. GustafsonDirector | sold | 5,474at $12.31 | 15 Jun 2026filed 17 Jun 2026 |
| Bart Jan CornelissenSR. VICE PRESIDENT & CFO | sold | 3,499at $12.29 | 10 Apr 2026filed 13 Apr 2026 |
| Bassil I. DahiyatPRESIDENT & CEO | sold | 6,606at $11.02 | 6 Mar 2026filed 9 Mar 2026 |
| John R. DesjarlaisSR. VICE PRESIDENT & CSO | sold | 2,502at $11.02 | 6 Mar 2026filed 9 Mar 2026 |
| Celia EckertSVP, GENERAL COUNSEL | sold | 1,767at $11.02 | 6 Mar 2026filed 9 Mar 2026 |
| Bassil I. DahiyatPRESIDENT & CEO | sold | 14,870at $11.25 | 5 Mar 2026filed 9 Mar 2026 |
| John R. DesjarlaisSR. VICE PRESIDENT & CSO | sold | 4,118at $11.25 | 5 Mar 2026filed 9 Mar 2026 |
| Celia EckertSVP, GENERAL COUNSEL | sold | 3,244at $11.25 | 5 Mar 2026filed 9 Mar 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| BlackRock, Inc.added · filed 7 Aug 2026 | 13,651,261$219.8M | +615,343+4.7% |
| PRIMECAP MANAGEMENT COreduced · filed 14 Aug 2026 | 10,181,322$163.9M | -156,700−1.5% |
| BVF INCunchanged · filed 14 Aug 2026 | 7,133,720$114.9M | 00.0% |
| RTW INVESTMENTS, LPunchanged · filed 14 Aug 2026 | 6,777,461$109.1M | 00.0% |
| RA CAPITAL MANAGEMENT, L.P.added · filed 14 Aug 2026 | 5,274,274$84.9M | +377,037+7.7% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 4,954,016$79.8M | +601,980+13.8% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 3,278,802$52.8M | +177,155+5.7% |
| TCG Crossover Management, LLCunchanged · filed 14 Aug 2026 | 2,452,138$39.5M | 00.0% |
| VANGUARD PORTFOLIO MANAGEMENT LLCreduced · filed 13 Aug 2026 | 2,215,690$35.7M | -1,284,652−36.7% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 1,920,859$30.9M | +105,282+5.8% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.